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Abstract: A novel bioactive peptide named τ-AnmTx Ueq 12-1 (short name Ueq 12-1) was isolated
and characterized from the sea anemone Urticina eques. Ueq 12-1 is unique among the variety of
known sea anemone peptides in terms of its primary and spatial structure. It consists of 45 amino
acids including 10 cysteine residues with an unusual distribution and represents a new group of sea
anemone peptides. The 3D structure of Ueq 12-1, determined by NMR spectroscopy, represents a new
disulfide-stabilized fold partly similar to the defensin-like fold. Ueq 12-1 showed the dual activity of
both a moderate antibacterial activity against Gram-positive bacteria and a potentiating activity on the
transient receptor potential ankyrin 1 (TRPA1). Ueq 12-1 is a unique peptide potentiator of the TRPA1
receptor that produces analgesic and anti-inflammatory effects in vivo. The antinociceptive properties
allow us to consider Ueq 12-1 as a potential analgesic drug lead with antibacterial properties.
Keywords: sea anemones; innate immunity; defensive strategies; TRPA1 receptor; antimicrobial
1. Introduction
The phylum Cnidaria (including corals, hydroids, jellyfish, sea anemones and sea pens) is
considered the oldest extant lineage of venomous animals, and species within this phylum are known
to produce a variety of bioactive compounds that they utilize for capturing and killing prey and for
defense [1]. All species within this phylum share a biological feature (which is likely due to common
ancestry), the nematocysts; these are special cells designed to penetrate the skin of other animals
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and inject a venomous cocktail of compounds during hunting or defense [2–4]. Numerous bioactive
peptides have been characterized from this phylum, including toxic and antimicrobial peptides,
with molecular weights ranging from 3 to 15 kDa.
Antimicrobial peptides (AMPs) comprise a very diverse group of peptides containing both
anionic and cationic, linear and cysteine-rich peptides [5]. Several AMPs have been characterized
from cnidarians, including hydramacin-1 and c-arminin 1a, both from Hydra magnipapillata [6,7],
periculin from Hydra vulgaris [8], aurelin from Aurelia aurita [9] and pd-AMP1, a 5.3 kDa peptide from
Phyllogorgia dilatata [10]. Among sea anemones, Anemonia sulcata produces neurotoxin-2, which is both
neurotoxic and proposed to be antimicrobial [11–13].
Sea anemones are well known producers of potent neuroactive peptides, acting on a diverse panel
of ion channels, such as voltage-gated sodium (NaV) and potassium (KV) channels, transient receptor
potential channels (TRP) and acid-sensitive ion channels (ASICs) [1,14–17].
The TRP superfamily of transmembrane non-selective ion-channels is involved in various
perceptions including nociception and is therefore a target for analgesic treatment. All channels
are believed to be tetrameric, consisting of subunits with six transmembrane domains [18,19].
Both antagonists and agonists of a number of these channels are promising drug candidates because
antagonists can provide immediate pain relief while agonists can provide desensitization over time.
The transient receptor potential ankyrin 1 ion channel (TRPA1) was first cloned [20] and was
identified as a receptor for noxious cold temperature [21]. Although controversy exists regarding
its role as a thermosensor, its role in nociception is quite clear [22]. Agonists of TRPA1 activate
sensory neurons in vivo causing acute pain, thermal and mechanical hyperalgesia and neurogenic
inflammation. This is similar to the transient receptor potential vanilloid 1 (TRPV1), which is usually
coexpressed with TRPA1 [23].
Urticina is a genus of sea anemones in the family Actiniidae. No antimicrobial peptides have
previously been characterized in the sea anemone Urticina eques. However, a putative Type 1 neurotoxin
(Ue-1) was discovered via RNA deep sequencing [24] and in the related species U. grebelnyi, a reversible
inhibitor of both transient and sustained ASIC3 currents was characterized by Osmakov et al. [16].
Additionally, the genus has given rise to the 30 kDa cytolytic protein UcI and the phospholipase
UcPLA2 of U. crassicornis [25,26], and the 28 kDa cardiac stimulatory and haemolytic protein UpI of
U. piscivora [27].
Since sea anemones in general are known to be producers of biologically active peptides and
owing to the fact that U. eques is largely unexplored, we aimed to isolate and identify new bioactive
peptides in U. eques. We managed to isolate and characterize a novel peptide with an unusual cysteine
distribution and a new molecular scaffold, providing both antimicrobial and antinociceptive properties.
2. Results
2.1. Isolation of Ueq 12-1
Specimens of the sea anemone U. eques were collected off the coast of Tromsø, Norway, and
ectoderm secretions/mucus were obtained by electrical stimulation. The released exudate containing
peptides and other hydrophobic components was desalted and concentrated using solid phase
extraction (SPE). The antibacterial effect of the extract was observed against the Gram-positive strain
Corynebacterium glutamicum at concentrations as low as 80 µg/mL. The same extract displayed an
inhibiting effect on the TRPA1 ion channel at 0.1 mg/mL but did not affect the TRPV1 and TRPV3
channels in the Fluo-4-based intracellular calcium assay (data not shown).
In order to identify fractions with bioactive components, the extract was fractionated by
preparative RP-HPLC (Figure 1). All the obtained fractions were subsequently tested for both
antibacterial and TRPA1 activities. The fraction eluting after 27 min displayed antibacterial activity
against C. glutamicum. In the Ca2+ influx assay, the same fraction was found to potentiate the TRPA1
ion channel (data not shown). The crude extract displayed a net inhibition of TRPA1, which is the
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opposite effect observed for the HPLC fraction: this is probably because of the presence of other
interfering bioactive compounds.
The bioactive fraction was shown to consist of a peptide with a monoisotopic molecular mass of
4788.63 Da, as measured by HR-ESI-MS.
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Measurements  of  the molecular mass  of  the  pyridylethylated  peptide  exceeded  that  of  the 
native peptide by 1061.5 Da. This increase in mass is attributable to the addition of 10 pyridylethyl 
groups (10 × 106.14 Da) on 10 alkylated cysteine residues, which forms five disulfide bonds in the 
original  peptide. A  partial N‐terminal  sequence  of Ueq  12‐1 was  successfully  determined  up  to 
residue 34 by Edman degradation: CYPGQPGCGHCSRPNYCEGARCESGFHDCGSDHW, showing 
6 of a total of 10 cysteines in the peptide. 
To  elucidate  the  complete  peptide  sequence,  degenerated  primers were  constructed  on  the 
basis  of  the  partial  primary  peptide  structure  and were  used  to  amplify  the  3′‐terminus  of  the 





encoding  the  precursor  (ENA  ID:  LT600337)  and  the  deduced  peptide  sequence  of Ueq  12‐1  is 
shown  in Figure 2. The complete deduced peptide sequence of Ueq 12‐1 contains 74 amino acids. 
Comparison of  the partial amino acid sequence  found by N‐terminal sequencing and  the peptide 
sequence deduced from cDNA revealed that the precursor contains a pre‐region of 29 amino acid 




acids.  Assuming  disulfide  bonds  between  the  10  cysteine  residues  the  deduced  peptide  has  a 
Figure 1. Isolation of Ueq 12-1 from U. eques mucus/secretions by reverse phase HPLC. A crude mucus
extract (obtained after electrical stimulation and desalting) from U. eques was pre-purified by solid
phase extraction and the eluate was subjected to RP-HPLC using a semi-preparative C5 column. Elution
was performed with a linear gradient of 0–60% acetonitrile for 60 min at a flow rate of 5 mL/min.
The fraction showing growth inhibitory activity against C. glutamicum and the ability to potentiate the
TRPA1 ion channel and the peak containing Ueq 12-1 are shown with a bold black line ().
2.2. Ueq 12-1 Amino Acid Sequence Determination
Measurements of the molecular mass of the pyridylethylated peptide exceeded that of the native
peptide by 1061.5 Da. This increase in mass is attributable to the addition of 10 pyridylethyl groups
(10 × 106.14 Da) on 10 alkylated cysteine residues, which forms five disulfide bonds in the original
peptide. A partial N-terminal sequence of Ueq 12-1 was successfully determined up to residue 34 by
Edman degradation: CYPGQPGCGHCSRPNYCEGARCESGFHDCGSDHW, showing 6 of a total of
10 cysteines in the peptide.
To elucidate the complete peptide sequence, degenerated primers were constructed on the basis
of the partial primary peptide structure and were used to amplify the 3′-terminus of the transcript,
using newly synthesized cDNA as a template. Using PCR with the universal primer T7Cap and
degenerated primers, a fragment of about 400 bp was obtained. The PCR product was cloned into a
pAL-TA vector and sequenced. Based on the nucleotide sequence of the found gene, reverse primers
UE-r1 and UE-r2 were synthesized for 5′-RACE. A DNA fragment of about 300 bp was obtained
after PCR and subsequently cloned into a pAL-TA vector and sequenced. The cDNA encoding the
precursor (ENA ID: LT600337) and the deduced peptide sequence of Ueq 12-1 is shown in Figure 2.
The complete deduced peptide sequence of Ueq 12-1 contains 74 amino acids. Comparison of the
partial amino acid sequence found by N-terminal sequencing and the peptide sequence deduced
from cDNA revealed that the precursor contains a pre-region of 29 amino acid residues upstream
of the mature Ueq 12-1 sequence. Analysis by SignalP 4.1 indicated that a cleavage site of a signal
peptide was located between amino acid Gly15 and Trp16 in the sequence. Thus, the precursor peptide
contains a signal peptide of 15 amino acids and a propeptide sequence between Trp16 and Arg29
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(14 amino acids) followed by the mature peptide consisting of 45 amino acids. Assuming disulfide
bonds between the 10 cysteine residues the deduced peptide has a calculated average mass of 4792.13
and a monoisotopic mass of 4788.62 Da. This mass is nearly identical to the monoisotopic mass of the
purified peptide as determined by HR ESI mass spectrometry (4788.63 Da). The mature peptide is
anionic with a net charge of −3 at neutral pH, and a calculated pI of 5.28.
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the Ueq  12‐1 precursor. The  signal  peptide  sequence  is underlined,  the  pro‐peptide  is  shown  in 
italic, and the mature Ueq 12‐1 peptide sequence  is marked  in bold. The polyadenylation signal  is 
double underlined while an asterisk denotes the stop codon. 
2.3. Production of Recombinant Ueq 12‐1 
To  obtain  larger  quantities  of  the  peptide  for  bioactivity  screening  and  structure‐function 
investigations,  an  Escherichia  coli  expression  system was  utilized. Ueq  12‐1 was  expressed  as  a 
fusion protein with  thioredoxin  (Trx), which promotes  the  folding  of  cysteine‐rich peptides  into 
their native conformation [28]. A synthetic gene product encoding Ueq 12‐1 was constructed from 
synthetic oligonucleotides by PCR and was cloned into the expression vector pET32b(+). The E. coli 
SHuffle  cells  were  transformed  by  the  resulting  construction  pET32b(+)‐Ueq  12‐1.  The  fusion 
protein  (Trx‐Ueq  12‐1) was  isolated using metal  affinity  chromatography,  and was  subsequently 
subjected  to  CNBr  cleavage  and  purification  by  reverse‐phase  HPLC  to  obtain  the  pure 
recombinant peptide. The recombinant Ueq 12‐1 had the same retention time as the native peptide 
when  fractionated  by  reverse‐phase  HPLC  (data  not  shown),  producing  the  same  effect  in 
electrophysiological  tests on TRPA1 and  in behavioral  tests  in mice. This  implies  that  they were 
identical. Moreover,  analysis  of  1H NMR  spectra  revealed  the  complete  identity  of  natural  and 
recombinant Ueq12‐1 samples at pH 3.0. The total yield of Ueq 12‐1 was approximately 0.7 mg per 
liter of bacterial culture. The average molecular mass of  the recombinant product, determined by 






program  [29]  from 100 random starting points using  the  following experimental data: upper and 
lower  NOE‐based  distance  restraints,  torsion  angle  restraints,  and  hydrogen  bonds  restraints 
(Figure 3). The statistics of the obtained set of Ueq 12‐1 structures are shown in Table 1. 
Figure 2. Compl te cDNA sequence (ENA ID: LT600337) and the educed amino acid s qu nce
of th Ueq 2-1 precu sor. The signal eptide sequence is underlined, the pro-peptide is shown in
italic, and the mature Ueq 12-1 peptide sequence is arked in bold. The polyadenylation signal is
double underlined while an asterisk denotes the stop codon.
2.3. Production of Recombinant Ueq 12-1
To obtain larger quantities of the peptide for bioactivity screening and structure-function
investigations, an Escherichia coli expression system was utilized. Ueq 12-1 was expressed as a fusion
protein with thioredoxin (Trx), which promotes the folding of cysteine-rich peptides into their native
conformation [28]. A synthetic ge e product encoding Ueq 12-1 was constructed from synthetic
oligonucleotides by PCR and was cloned into the expression vector 32b( ). The E. coli SHuffle cells
were transformed by the resulting construction pET32b(+)-Ueq 12-1. The fusion protein (Trx-Ueq 12-1)
was isolated using metal affinity chromatography, and was subsequently subjected to CNBr cleavage
and purification by reverse-phase HPLC to obtain the pure recombina t peptide. The recombinant
Ueq 12-1 had the same retention time as the native peptide when fracti nated by reverse-phase HPLC
(data not sh wn), producing the same effect in electrophysiological tests on TRPA1 and in behavioral
tests in mice. This implies that they were identical. Moreover, analysis of 1H NMR spectra revealed
the complete identity of natural and recombinant Ueq12-1 samples at pH 3.0. The total yield of Ueq
12-1 was approximately 0.7 mg per liter of bacterial culture. The average molecular mass of the
recombinant product, determined by MALDI mass spectrometry (4792.60 Da), was in accordance with
the theoretical mass calculated from the sequence data (4792.13 Da), and the average ass of the native
peptide measured by HR ESI mass spectrometry (4792.45 Da).
2.4. Spatial Structure of Ueq 12-1 in Water Solution
In order to determine the fold of Ueq 12-1, the structure of the protein was resolved in water
solution by NMR spectroscopy. A set of 20 possible structures was calculated using the CYANA
program [29] from 100 random starting points using the following experimental data: upper and lower
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NOE-based distance restraints, torsion angle restraints, and hydrogen bonds restraints (Figure 3).
The statistics of the obtained set of Ueq 12-1 structures are shown in Table 1.
The set of structures is characterized by a relatively low CYANA target function and residual
restraint violations, and a low RMSD value for backbone atoms, suggesting that the structure of Ueq




restraint violations, and a  low RMSD value  for backbone atoms,  suggesting  that  the  structure of 
Ueq 12‐1 is well‐converged and defined accurately by the experimental data. 
 
Figure  3.  Overview  of  the  NMR  data,  defining  the  secondary  structure  of  Ueq  12‐1. 
Hydrogen‐deuterium  exchange  rates  of  HN  protons  with  solvent  (H‐D  ex),  3JHNHα  couplings, 


































According  to  the NMR data, Ueq 12‐1  is organized  in a peculiar W‐shaped structure  (Figure 
4A,B). The core of the structure is formed by a 3‐strand antiparallel β‐sheet (strands Y16–E18, H27–
Figure 3. Overview of the NMR data, defining the secondary structure of Ueq 12-1. Hydrogen-
deuterium exchange rates of HN protons with solvent (H-D ex), 3JHNHα couplings, secondary structure
of Ueq 12-1 (SS) and NOE connectivities (dij) are shown versus the protein sequence. Widths of the
bars correspond to the relative intensity of cross-peak in t e 80 ms NOESY spectrum. Circles denote
HN protons, which exchange with solven with characteristic times lon r than 15 min. Black, gray and
white ectangles denote residues with larg (>8 Hz), medium (6–8 Hz) or small (<6 Hz) magnitudes of
3JHNHα, respectively. Elements of secondary structure are shown on the separate line, β-strands are
indicated by arrows, color of arrows indicates the involvement of strand in parallel (grey) or antiparallel
(white) β-sheet.
Table 1. Statistic for the best Ueq 12-1 structures and NMR input data.




sequential (|i − j| = 1) 104
Medium range (1 < |i − j| ≤ 4) 36
Long range (|i − j| > 4) 80
Hydrogen bond restraints (upper/lower) 56/56




Total restraints/per residue: 523/12
Statistics of calculated set of structures
CYANA target function (Å2) 1.77 ± 0.04
Restraint violations
distance (>0.2 Å) 3
angle (>5◦) 0
RMSD (Å) Elements with defined structure (6–27)
Backbone 0.38 ± 0.15
All heavy atoms 1.03 ± 0.14
Ramacha dran analysis
% residues in most favored regions 75.8
% residues in additional allowed regions 21.2
% residues in generously allowed regions 3.0
% residues in disallowed regions 0.0
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According to the NMR data, Ueq 12-1 is organized in a peculiar W-shaped structure (Figure 4A,B).
The core of the structure is formed by a 3-strand antiparallel β-sheet (strands Y16–E18, H27–D28
and R41–C44), a small 2-strand parallel β-sheet (G9–H10, H33–W34) and one turn of a 3–10 helix
(G30–D32). The obtained structure consists of three large loops including 8 β-turns of various types
(Y2–Q5, IV; Q5–C8, IV; S12–N15, VIa1; R13–Y16, IV; E18–R21, IV; E23–F26, IV; C35–S38, VIII; A37–D40,
IV) and it is stabilized by 5 disulfide bridges (C1–C8, C11–C42, C17–C35, C22–C43 and C29–C44).
Analysis of the hydrogen-deuterium exchange rates of the protein amide groups revealed 19 hydrogen
bonds. Besides, a number of aromatic and negatively charged residues in one of the loops of Ueq 12-1
that are involved in stacking and π-anion interactions are observed (Y16, F26, E18, E23). The surface




D28 and R41–C44), a  small 2‐strand parallel  β‐sheet  (G9– 10, H33–W34) and one  turn of a 3–10 
helix (G30–D32). The obtained structure consists of three large loops including 8 β‐turns of various 
types (Y2–Q5, IV; Q5–C8, IV; S12–N15, VIa1; R13–Y16, IV; E18–R21, IV; E23–F26, IV; C35–S38, VIII; 
A37–D40,  IV) and  it  is stabilized by 5 disulfide bridges (C1–C8, C11–C42, C17–C35, C22–C43 and 
C29–C44).  Analysis  of  the  hydrogen‐deuterium  exchange  rates  of  the  protein  amide  groups 
revealed 19 hydrogen bonds. Besides, a number of aromatic and negatively charged residues in one 
of the loops of Ueq 12‐1 that are involved in stacking and π‐anion interactions are observed (Y16, 
F26, E18, E23). The  surface  of  the peptide  is polar without pronounced  clusters  of positively  or 
negatively charged side chains (Figure 4C,D). 
 
Figure 4. Two‐sided view of  the determined spatial structure of Ueq 12‐1  (PDB ID: 5LAH).  (A,B) 
Ribbon  representation.  Disulfide  bridges,  positively  and  negatively  charged  side  chains  and 
aromatic  residues  are  shown  by  yellow,  red,  blue  and  orange  sticks,  respectively;  (C) 





selected bacterial strains. The  test bacteria were represented by  two Gram‐negative strains  (E. coli 
and P. aeruginosa) and two Gram‐positive strains (S. aureus and C. glutamicum). The three strains (E. 




they have  limited  ecological  relevance. The peptide had moderate  activity  against C.  glutamicum 
Figure 4. Two-sided view of the determined spatial structure of Ueq 12-1 (PDB ID: 5LAH).
(A,B) Ribbon representation. Disulfide bridges, positively and negatively charged side chains and
aromatic residues are shown by yellow, red, blue and orange sticks, respectively; (C) Hydrophobicity
of the Ueq 12-1 surface. Contact surface of Ueq 12-1 is colored from yellow (hydrophobic) to green
(hydrophilic), according to the molecular hydrophobic potential (MHP) [30]; (D) molecular surface of
Ueq 12-1 is painted according to the electrostatic potential.
2.5. In Vitro Antimicrobial Activities of Ueq 12-1
Ueq 12-1 was purified in its natural form and its antimicrobial potential was estimated against
selected bacterial strains. The test bacteria were represented by two Gram-negative strains (E. coli and
P. aeruginosa) and two Gram-positive strains (S. aureus and C. glutamicum). The three strains (E. coli,
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P. aeruginosa and S. aureus) are all relevant laboratory strains, similar to disease-causing bacterial strains
in humans. C. glutamicum was chosen because of high sensitivity to antimicrobial compounds which
increases the possibility of detecting minimal amounts of antimicrobial peptides [31]. As far as we
know, none of these bacterial strains cause disease in sea anemones. Therefore, they have limited
ecological relevance. The peptide had moderate activity against C. glutamicum (MIC = 50 µM), but







Figure 5. Antibacterial activity  toward C. glutamicum of Ueq 12‐1  in  concentrations  ranging  from 




a  stably  transfected  Chinese  Hamster  Ovary  (CHO)  cell  line  up  to  35  ±  10%  at  1  μM.  The 
electrophysiological effect of Ueq 12‐1 was tested on TRPA1 expressed in Xenopus laevis oocytes. At 
240 μM, Ueq 12‐1 did not cause any current  in  the TRPA1‐expressing oocytes, but  it significantly 
potentiated  the  activation  of  TRPA1  induced  by AITC  or  diclofenac. Dose‐response  analysis  of 
potentiation  was  carried  out  using  oocytes  activated  by  300  μM  diclofenac  (Figure  6).  At 








peptide  (Figure  6E).  The  same  potentiating  effect  of  peptide  was  observed  for  AITC‐induced 
currents of TRPA1 (Figure 6F). Ueq 12‐1 at a concentration of 60 μM produced neither agonistic nor 
antagonistic  activity  on  rat TRPV1  and  human TRPV3  receptors  in  fluorescent  assay  of  calcium 
influx in CHO cell lines stably expressing these receptors. 
Figure 5. Antibacterial activity toward C. glutamicum of Ueq 12-1 in concentrations ranging from 12.5
to 200 µM. The peptide is antibacterial in concentrations ≥50 µM. OTC (tetracycline) (40 µM) and H2O
served as controls.
2.6. Effect of Ueq 12-1 on TRPA1 Activity
Ueq 12-1 was found to potentiate the allyl isothiocyanate (AITC) induced TRPA1 Ca2+
influx in a stably transfected Chinese Hamster Ovary (CHO) cell line up to 35 ± 10% at 1 µM.
The electrophysiological effect of Ueq 12-1 was tested on TRPA1 expressed in Xenopus laevis oocytes.
At 240 µM, Ueq 12-1 did not cause any current in the TRPA1-expressing oocytes, but it significantly
potentiated the activation of TRPA1 induced by AITC or diclofenac. Dose-response analysis of
potentiation was carried out using oocytes activated by 300 µM diclofenac (Figure 6). At concentrations
ranging from 0.3 to 27 µM, Ueq 12-1 moderately potentiated TRPA1 outward currents up to 120–135%
and inward currents up to 132–186% (Figure 6A,B). Higher concentration of the peptide caused
significantly more potentiation of the TRPA1 currents (at 60 µM − 200 ± 23% (outward) and
378 ± 65% (inward); at 120 µM − 453 ± 104%(outward) and 719 ± 98% (inward), data shown as
mean ± SD) (Figure 6C,D). Application of Ueq 12-1 at a concentration of 240 µM (together with
diclofenac) dramatically increased the TRPA1 outward and inward currents up to 835 ± 566% and
2559 ± 959%, respectively (Figure 6C,D). At concentrations above 750 µM, Ueq 12-1 caused no standard
response to agonist, probably due to defunctionalization of the receptor in the presence of peptide
(Figure 6E). The same potentiating effect of peptide was observed for AITC-induced currents of TRPA1
(Figure 6F). Ueq 12-1 at a concentration of 60 µM produced neither agonistic nor antagonistic activity
on rat TRPV1 and human TRPV3 receptors in fluorescent assay of calcium influx in CHO cell lines
stably expressing these receptors.





Figure 6. TRPA1  currents evoked  in  response  to exposure  to diclofenac  (300  μM) and AITC  (100 
μM)  in  the presence of Ueq 12‐1.  (A)  representation  trace  for potentiating effect of Ueq 12‐1 at a 
concentration of 9 μM on diclofenac‐induced currents; (B) data on potentiating activity of peptide at 
a  concentration  of  3–30  μM  on diclofenac‐induced  currents  (shown  as mean  ±  SD,  n  =  5–7);  (C) 
representation trace for potentiating effect of Ueq 12‐1 at a concentration of 60–240 μM; (D) data on 
potentiating  activity  of  peptide  at  a  concentration  of  60–240  μM  on  diclofenac‐induced  currents 






injected  into  the mice  to provoke pain behavior associated with TRPA1 activation. The dosage of 
AITC was  chosen  to  induce half‐maximal  effect  (20  μL,  0.5%  in  saline). Pretreatment of mice by 
intravenous  injection  of  Ueq  12‐1  (0.2  mg/kg)  significantly  reduced  AITC‐induced  nocifensive 
behavior.  Paw  licking  and  time  spent  guarding  were  significantly  decreased  (49%  and  43% 
reduction, respectively) in the Ueq 12‐1 treated mice (Figure 7A). Moreover, paw edema caused by 
AITC was significantly reduced by 39 and 57% 2 and 4 h after  injection, respectively  (Figure 7B). 
Additionally,  the  influence  of  intravenous  injection  of  Ueq  12‐1  (0.2  mg/kg)  on  non‐specific 
inflammation was  tested  using  the  Complete  Freund’s Adjuvant  (CFA)  test.  Inflammation was 
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Figure 6. TRPA1 currents evoked in response to exposure to diclofenac (300 µM) and AITC (100 µM) in
the presence of Ueq 12-1. (A) representation trace for potentiating effect of Ueq 12-1 at a concentration
of 9 µM on diclofenac-induced currents; (B) data on potentiating activity of peptide at a concentration
of 3–30 µM on diclofenac-induced currents (shown as mean ± SD, n = 5–7); (C) representation trace
for potentiating effect of Ueq 12-1 at a concentration of 60–240 µM; (D) data on potentiating activity
of peptide at a concentration of 60–240 µM on diclofenac-induced currents (shown as mean ± SD,
n = 5–7); (E) representation trace for defunctionalization of TRPA1 in the presence of Ueq 12-1 at a
concentration of 750 µM; (F) representation trace for potentiating effect of Ueq 12-1 at a concentration
of 60 µM on AITC-induced current.
2.7. In Vivo Bioactivites of Ueq 12-1
Injection of Ueq 12-1 (10 µL, 50 µM solution) into the mouse hind paw did not cause pain, paw
edema or significant thermal hyperalgesia during the 2 h experiment. The TRPA1 agonist AITC
was injected into the mice to provoke pain behavior associated with TRPA1 activation. The dosage
of AITC was chosen to induce half-maximal effect (20 µL, 0.5% in saline). Pretreatment of mice
by intravenous injection of Ueq 12-1 (0.2 mg/kg) significantly reduced AITC-induced nocifensive
behavior. Paw licking and time spent guarding were significantly decreased (49% and 43% reduction,
respectively) in the Ueq 12-1 treated mice (Figure 7A). Moreover, paw edema caused by AITC was
significantly reduced by 39 and 57% 2 and 4 h after injection, respectively (Figure 7B). Additionally,
the influence of intravenous injection of Ueq 12-1 (0.2 mg/kg) on non-specific inflammation was tested
using the Complete Freund’s Adjuvant (CFA) test. Inflammation was induced by injection of CFA
into the hind paw and Ueq 12-1 (0.2 mg/kg) was administrated 24 h afterward. Ueq 12-1 reversed
thermal hyperalgesia within 30 min after i.v. administration (Figure 7C) and decreased paw edema by
27% 24 h after injection (Figure 7D). Pre-treatment of mice by selective TRPA1 antagonist A-967079
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(20 mg/kg, p.o. 1 h before peptide) completely blocked the effect of peptide Ueq 12-1 (0.2 mg/kg, i.v.)
on CFA-induced inflammation (Figure 8).
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effect of Ueq 12‐1 on  the mice withdrawal  latency on a hot plate  in  the  thermal hyperalgesia  test 
after CFA  injection and  (D) on CFA‐induced paw  inflammation  (0.2 mg/kg). Results presented as 
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Figure 7. Efficacy of the peptide Ueq 12-1 in animal models. (A) Ueq 12-1 (0.2 mg/kg, i.v.) significantly
reduce behavioral response and (B) inflammatory response to injection of AITC; (C) effect of Ueq 12-1
on the mice withdrawal latency on a hot plate in the thermal hyperalgesia test after CFA injection and
(D) on CFA-induced paw inflammation (0.2 mg/kg). Results presented as mean ± SEM; ***, p < 0.001;
**, p < 0.01; *, p < 0.05; versus saline group (ANOVA followed by a Tukey’s test); n = 7 for all experiments.
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Figure 8. Selective TRPA1 antagonist A-967079 (20 mg/kg, p.o.) completely blocked the effect of
peptide Ueq 12-1 (0.2 mg/kg, i.v.) on thermal hyperalgesia (n = 7–8).
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The response to the peptide observed in the behavioral tests was not a result of sedation or
behavior impairment because administration of Ueq 12-1 did not change the normal behavior of mice
in the open field test (results not shown).
3. Discussion
Sea anemones are known to produce an array of biologically active peptides of different structures
and folds, and many of them are promising for pharmaceutical drug development [1]. Sea anemone
toxins comprise mainly proteins and peptides that are cytolytic or neurotoxic, with their potency
varying with the structure, target molecule and mechanism of action. Sea anemone toxins include
voltage-gated Na+ and K+ channels toxins, acid-sensing ion channels (ASIC) toxins, cytolysins,
Kunitz-type protease inhibitors and toxins with Phospholipase A2 activity [1,32]. In the present
study, we have isolated and characterized a novel peptide Ueq 12-1 with a unique disulfide fold that
possesses both antimicrobial and antinociceptive properties.
3.1. Primary Structure Analysis of Ueq 12-1
Ueq 12-1 is a 45-amino acid anionic peptide containing 10 cysteines engaged in five intramolecular
disulfide bonds. No significantly homologous peptides were found in the databases. Based on
earlier results, sea anemones may be considered leaders among the venomous animals in terms of the
structural variety of polypeptides in their venoms and mucus. Polypeptides from the animal venom
usually contain an even number of cysteine residues normally involved in the formation of disulfide
bonds forming a rigid structure, more resistant to proteolysis [17,33].
Ueq 12-1 displays no sequence homology to known characterized sea anemone neurotoxins.
The majority of characterized cysteine-rich peptides from sea anemones consist of 25–60 amino acid
residues, 4–10 cysteine residues and a considerable number of positively charged residues (Lys, Arg)
forming positively charged clusters on the surface [1,34]. Almost 50% of the reported peptides are
ligands of sodium or potassium channels, and positively charged and hydrophobic residues play a
leading role in toxin-channel interaction.
A classification of SWISS PROT annotated cysteine-rich sea anemone peptides by their cysteine
distribution has recently been developed [32]. All the annotated peptides are classified into 11 families
with characteristic cysteine patterns that suggest 11 variants of polypeptide folding. Furthermore,
at least 16 different motifs of cysteine distribution in the polypeptides have been identified [32].
The peptide Ueq 12-1 has a unique cysteine pattern and therefore it cannot be assigned to any of the
11 distinct structural subfamilies of the known sea anemone peptides. Ueq 12-1 thus represents a new
family of peptides with the motif C6C2C5C4C6C5C6CCC# (where # is 1 − 9 aa). The given full name
is τ-AnmTx Ueq 12-1 (short name Ueq 12-1). This means that the peptide is the first representative of a
12th subgroup according to the classification proposed by Mikov [32].
No highly homologous peptides or gene products were found using the NCBI BLAST
search engine in non-redundant protein sequences (nr) database and Transcriptome shotgun
assembly proteins (Tsa_nr) database or within searchable antimicrobial peptide databases. Even
the StellaBase (the Nematostella vectensis genomics database), Pocillopora Transcriptomics Database
(Pocillopora damicornis, cauliflower coral) and EdwardsiellaBase (the Edwardsiella lineata Genomic
Database) returned no homologous sequences. Furthermore, no conservative protein domains were
detected using the InterProScan tool.
We found some similarities in the cysteine distribution pattern with small cysteine-rich peptides
(SCRiPs) from corals and sea anemones extracted from EST databases [35]. Additionally, one cDNA
coding for SCRiP peptide (TSA: Anthopleura elegantissima comp63456_c0_seq1 transcribed RNA
sequence, GBYC01024820.1) similar to Ueq 12-1 was found in Transcriptome shotgun assembly (TSA)
database using TBLASTN search. We should note that a variety of different cDNAs coding for SCRiPs
peptides could be identified in the TSA database using known SCRiPs as a query and TBLASTN search
in Cnidarians transcriptomes but the homology of SCRiPs from different species is very low.
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An identifying feature for both Ueq 12-1 and SCRiPs is a triplet of cysteines located in the
C-terminus (Figure 9). Since all SCRiPs sequences are deduced from cDNA, no data is available
regarding their function and spatial structure. SCRiPs contain only eight cysteine residues, and
their distribution is similar to the eight C-terminal cysteines of Ueq 12-1 (Figure 9). Apart from the
cysteine-motif, there is no significant primary structure homology between Ueq 12-1 and SCRiPs. Most
probably, Ueq 12-1 and SCRiPs reflect the evolution of an ancient venom component and a common
evolutionary origin of cnidarian toxins [35].
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Figure 9. Sequence alignment of Ueq 12-1 (UniProt Protein Database ID: C0HK26) and small
cysteine rich peptides (SCRiPs). TSA: A. el. − peptide obtained from TSA: Anthopleura elegantissima
comp63456_c0_seq1 transcribed RNA sequence, GBYC01024820.1 by translation. C0H690 Acropora
millepora (SCRiP1); C0H691 A. millepora (SCRiP2); C0H692 A. millepora (SCRiP3); C0H693 Montipora
capitata (SCRiP1a); FK725749 Anemonia viridis; and FC835414 Metridium senile. The residues identical to
Ueq 12-1 are highlighted in bold.
3.2. Spatial Structure Analysis of Ueq 12-1
Analysis of the spatial structure of Ueq 12-1 revealed significant similarity to some defensin-like
peptides of mammals, platypus and some sea anemone toxins of the disulfide-rich, nearly all-β
structural defensin-like fold (SCOP family g.9.1.1) [36]. Analysis of the 3D structure homology using
the PDBeFold analysis tool [37] revealed that Ueq 12-1 could be aligned with the spatial structures of
several peptides (Table 2 and Figure 10). These were the mouse alpha-defensin 4 (Cryptdin-4, 1tv0), the
defensin-like peptide from platypus venom DLP-2(4) (1zue, 1zuf), the human beta-defensins HBD-2
and HBD-1 (1e4q, 1e4s), the plant cyclotyde Kalata-B12 (2kvx), and two peptide toxins derived from
sea anemones: Anthopleurin-A (1ahl) and CGNA toxin (2h9x). Thus, despite the absence of homology
in the primary structure, the backbone of peptide Ueq 12-1 forms a similar to defensin-like peptides
fold (Figure 10, Table 2). It is also noteworthy that Ueq 12-1 is less similar to sea anemone defensin-like
peptides compared to mammalian defensins. The significance of structural alignment was evaluated
by the Q-score that represents the quality function of Cα-alignment, maximized by the Secondary
Structure Matching (SSM) alignment algorithm. This is a complex characteristic, which takes into
account both the alignment length and the RMSD (Root Mean Square Deviation, calculated between
the Cα-atoms of the matched residues in the best 3D superposition of the query and target structures).
It is important to note that the Q-score was rather low (0.46–0.38) for the peptides that have a
defensin-structure domain such as the mouse alpha-defensin 4 (1tv0), DLP-2(4) (1zue, 1zuf) and hBD2
(1e4q), and it was very low (~0.25) for the sea anemone defensin-like peptides anthopleurin-A (1ahl)
and CGNA toxin (2h9x). For comparison, the Q-score for the structural alignment of anthopleurin-A
(1ahl) and CGNA toxin (2h9x) was 0.7; for DLP-4 (1zuf) and hBD2 (1e4q) it was 0.52; and for
alpha-defensin 4 (1tv0) and beta-defensin hBD2 (1e4q) it was 0.47.
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Table 2. PDBeFold structure alignment results of Ueq 12-1 (PDB ID: 5LAH). The Q-score is calculated
as Q = Nalgn×Nalgn/((1 + (RMSD/R0)2)×Nres1×Nres2) where R0 = 3 Å, The Z-score measures the












Cryptdin-4, alpha-defensin from mouse, a-defenM4, Crp4 1tv0 32 29 21 0.46 4.2 1.54
Revised solution structure of platypus DLP-2 1zue 42 38 13 0.40 4.0 2.85
Human defensin HBD-2 1e4q 37 34 18 0.39 3.7 2.67
DLP-4 from platypus 1zuf 42 38 13 0.38 3.1 3.00
Human defensin HBD-1 1e4s 36 31 19 0.38 5.5 2.24
Kalata B12 from Oldenlandia affinis 2kvx 28 22 14 0.31 2.8 1.42
Anthopleurin-A from the sea anemone Anthopleura xanthogrammica 1ahl 49 30 23 0.26 5.3 2.27
CGNA toxin from the sea anemone Condylactis gigantea 2h9x 47 30 20 0.25 5.0 2.50
All the defensin/defensin-like peptides described above contain 6 cysteines in their primary
structure that form 3 disulfide bridges, whereas Ueq 12-1 contain 10 cysteines and 5 disulfide bridges.
Furthermore, none of these peptides contain the CCC motif in the C-terminus found in Ueq 12-1.
There are two types of defensins differing in disulfide bond configuration. In α-defensins (1tv0),
the three disulfide bridges have the topology C1–C6, C2–C4, C3–C5, whereas the disulfide arrangement
of β-defensins (1e4q, 1zue, 1e4s, 1ahl, etc.) is C1–C5, C2–C4, C3–C6 [38] (Figure 10). In Ueq 12-1, the
cysteine residues are paired in a C1–C2, C3–C8, C4–C7, C5–C9, C6–C10 configuration. The disulfide
bridges C3–C8, C4–C7, C5–C9 of Ueq 12-1 correspond to the β-defensin linkage, whereas the C1–C2
and C6–C10 pairings are additional bonds, which is characteristic for this peptide (Figure 10B).
The disulfide bond C1–C2 stabilizes the unique N-terminal loop of Ueq 12-1.
A defensin-like structural fold is shown for the sea anemone neurotoxins and is referred to as
structural group 1. These peptides affect a variety of cellular targets such as sodium, potassium and
acid-sensing channels. The closest structural homologues of Ueq 12-1 isolated from sea anemones
are sodium channels toxins rather similar in primary structure (~50% of identity): Anthopleurin-A
(1ahl) from Anthopleura xanthogrammica [39] and CGNA toxin (2h9x) from Condylactis gigantea [40].
Both are referred to as group 1a toxins [32]. Anthopleurin-A is a 49-residue polypeptide that produces
delayed inactivation of the myocardial voltage gated Na+ channel [41]. The CGNA toxin contains
47 amino acid residues and act on tetrodotoxin-sensitive voltage-gated sodium channels, increasing
the inactivation time constant and the rate of recovery from inactivation [40]. Both toxins contain
6 cysteines, but only one (C3–C6) of the three disulfide bridges is similar to Ueq 12-1 in the structural
alignment (Figure 10B).
Figure 10A is also a schematic representation of the secondary structural elements of Ueq 12-1
and defensin-like peptides. A considerable part of the Ueq 12-1 molecule is arranged very similarly to
the defensin-like fold that is also found in some bioactive peptides derived from sea anemones and
platypus. All the known mammalian defensins adopt a similar overall structure, i.e., a triple-stranded
antiparallel β-sheet [38]. The core of the Ueq 12-1 structure is also formed by a 3-strand antiparallel
β-sheet (strands Y16–E18, H27–D28 and R41–C44). Significant dissimilarities of the Ueq 12-1 structure
from the defensin-like peptides are the additional small 2-strand parallel β-sheet (G9–H10, H33–W34)
and one turn of a 3–10 helix (G30-D32) (Figures 3 and 9). Moreover, Ueq 12-1 has an unusual cysteine
distribution similar to previously reported SCRiPs. Nothing is known about the SCRiPs spatial
structure but it has been shown that some of them could be toxic against Danio rerio at rather high
concentrations (230 µg/mL) [35]. Based on our data on the spatial structure of Ueq 12-1, SCRiPs
most likely also have a defensin-like fold, as their cysteine distribution is similar to the defensin-like
domain of Ueq 12-1. Some of the SCRiPs could therefore also have antimicrobial properties and target
neuronal channels.
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and  platypus.  All  the  known  mammalian  defensins  adopt  a  similar  overall  structure,  i.e.,  a 
triple‐stranded  antiparallel  β‐sheet  [38].  The  core  of  the Ueq  12‐1  structure  is  also  formed  by  a 
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Figure 10. Comparison of Ueq 12-1 with other defensin like-peptides. (A) Schematic representation of
the secondary structures of Ueq 12-1 and defensin/defensin-like peptides; (B) The primary structure
alignment is based on spatial structure homology with the mouse alpha-defensin 4 (1tv0), HBD1 (1e4s)
and CGNA toxin (2h9x). The amino acid sequences are aligned according to equivalent topological
structure as determined by the PDBeFold algorithm. Beta-strands are shown with arrows. Residues
that entered spatial alignment are shown in shades of cyan, whereas residues with distance between Cα
atoms more than 3 Å are shown in small letters. Similar disulfide bonds are shown in red; (C) Backbone
spatial alignments for Ueq 12-1 and defensin-like peptides −mouse alpha-defensin 4 Crp4 (1tv0) and
CGNA toxin (2h9x) (D) Names and PDB codes of peptides.
3.3. Bioactivity Analysis of Ueq 12-1
Ueq 12-1 is one of the m in components found in U. eques ectoderm mucus/secretion . The peptide
seems to display differ nt defe se and offense functio because it inh bits bacterial cell growth and
potentiates the TRPA1 ion channel in vitro. Antibacterial activity can be useful for decreasing the
prob bility of infection after damage in vivo, and the effect on TRP chan els could mislead prey,
pr dators or compe itive species on th sea floor. TRPA1-like proteins are very conserved, take part in
mechanosensitivity and response to external stimuli [42]. For instance, TRPA1-like io channels in s a
anemones seem to be responsible for vibration-dependent discharge of nema ocysts [43]
The two different biological activities of Ueq 12-1 were discovered independently. Ueq 12-1
significantly inhibited growth of the Gram-positive C. glutamicum at 50 µM. This effect could be
associated with the partial defensin-like structure found in Ueq 12-1, as defensins are known to have
antibacterial activities [38].
The capability of defensins to interact with microbial membranes is determined by the shape
of the molecules, the ratio of polar to hydrophobic residues on the peptide surface, and the total
positive charge given through basic amino acids rather than by their individual primary structures [44].
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Usually, increasing the overall positive charge will increase the antimicrobial activity of AMPs due to
the selective action of AMPs on negatively charged bacterial membranes. Indeed, the AMP cryptidin-4
(Crp4, charge +8) more effectively associates with negatively charged biological membranes than
neutral membranes [45]. The antimicrobial activity of Ueq 12-1 is most probably associated with other
structural elements, as the peptide is negatively charged at neutral pH (pI = 5.28) but still maintains
antimicrobial activity. Meanwhile, the triple-stranded β-sheet with its specific arrangement of disulfide
bridges in defensins only provides stability to their structures, but is not an obligate determinant of
antimicrobial activity [44].
TRPA1 is a nonselective cation channel that is mainly expressed in sensory neurons and is
activated by exogenous electrophilic compounds (and a few other chemicals) as well as endogenous
ligands produced during inflammation or oxidative stress [46]. TRPA1 activation in the sensory
neurons produce both signals of pain or itching to the CNS and the release of pro-inflammatory
peptides provoking local inflammatory responses [42,46]. The TRPA1 receptor is therefore considered
a potential target for novel anti-inflammatory and analgesic drugs. In this study, Ueq 12-1 significantly
potentiated the response of TRPA1 to AITC and diclofenac in Ca2+ imaging and electrophysiological
experiments. However, we could not obtain a classical dose-response curve for the potentiating effect
because the peptide at high concentrations completely blocked the response of the receptor. This is an
unusual result, as the only known peptide potentiating TRPA1, Ms 9a-1 from sea anemone Metridium
senile, had the standard concentration-depended effect. [47].
Ueq 12-1 was found to be a bifunctional molecule displaying both antimicrobial and TRPA1
receptor potentiating activity (Figures 5 and 6). Multifunctionality seems to be a common feature of
sea anemone peptides. For instance, they may combine serine protease inhibitor properties with the
inhibition of voltage-gated potassium channels [48,49] or the TRPV1 receptor [17,50]. The defensin-like
peptide neurotoxin 2 (ATX-II) isolated from the sea anemone Anemonia sulcata was reported to affect
sodium channels gating and have antimicrobial properties [11]. This multifunctionality can be an
optimal strategy for the construction of biologically active peptides allowing sea anemones to be active
predators through the production of neurotoxins and resist bacterial infections caused by the eventual
injury of the tentacles. It is noteworthy that human β-defensin 2 (Hbd-2), the structural homologue
of Ueq 12-1, possess antimicrobial properties, act as an opener of large-conductance Ca2+-activated
potassium (BKCa)-mSlo+hβ1 channels and inhibit Kv1.3-channels [38,51,52]. These studies highlight
the multifunctionality observed for this particular spatial fold.
Injection of Ueq 12-1 into mice did not cause pain or hyperalgesia. Ueq 12-1 produced a significant
reduction of pain response to AITC, a TRPA1 agonist, and reduced CFA-induced hyperalgesia and
inflammation (Figure 7). Most probably, this peptide can potentiate and defunctionalize the TRPA1
receptor on sensory neurons or desensitize neurons. Inhibition of the TRPA1 function in vivo by
antagonist A-967079 eliminated the effect of Ueq 12-1 on thermal hyperalgesia (Figure 8). Therefore,
activation of TRPA1 is crucial for Ueq 12-1 analgesic effect of Ueq 12-1. In our study, defunctionalization
of the TRPA1 receptor was achieved only at extremely high concentrations of the peptide, but in
mammals, a great number of endogenous TRPA1 modulators can affect receptor activation [42,46] and
change sensitivity to the peptide. Additionally or alternatively, Ueq 12-1 can potentiate the activation
of TRPA1 to low concentrations of endogenous agonists, producing weak but sustained activation
of the receptor that leads to desensitization of TRPA1-expressing neurons. Such an effect of weak
activation of TRPA1 on the function of neurons has been shown for parthenolide, a partial agonist of
TRPA1, isolated from the flower feverfew (Tanacetum parthenium) [53]. Parthenolide is considered the
main component of feverfew that is responsible for the anti-migraine effect of this herbal remedy [53].
Therefore, potentiation/desensitization of TRPA1 ion channels might be an efficient treatment of pain
and inflammation.
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4. Conclusions
We should conclude that τ-AnmTx Ueq 12-1 is a unique, natural peptide possessing a new spatial
structure fold, exhibiting an antimicrobial activity, potentiating TRPA1, and producing an analgesic
effect in animal models of pain. Therefore, Ueq 12-1 could be considered as potential analgesic drug
lead with antibacterial properties.
5. Materials and Methods
5.1. Animal Material and Sample Preparation
Live specimens of Urticina eques (Gosse, 1858) were collected by divers off the coast of Tromsø,
Norway, during the summer/autumn of 2012. The animals were placed in tubs with continuously
flowing, unaltered seawater (4–8 ◦C), from one to eight weeks before sampling.
The approach for electrical stimulation is inspired by the work of [54] where antimicrobial
peptides were harvested from skin/mucus secretions of frogs. Ectoderm secretions were collected by
removing the specimens from the tubs and subjecting them to electrical stimulation with a constant
current of 300 mA, a non-fixed voltage of 10 Hz, and an impulse duration of 10 ms. The released
exudate was rinsed of the animals with a 10 mM ethylenediaminetetraacetic acid (EDTA)/0.1 mM
phenylmethylsulfonyl fluoride (PMSF) solution and centrifuged.
Salt was removed from the aqueous supernatant by reversed phase solid phase extraction (RP-SPE)
using a Supelco visiprep vacuum manifold (Sigma-Aldrich, St. Louis, MO, USA) with a C18 35cc
Sep-Pak cartridge (Waters, Milford, MA, USA). The cartridge was conditioned with acetonitrile
(MeCN)/0.05% trifluoroacetic acid (TFA) and equilibrated with 0.05% TFA. After sample loading,
the cartridge was washed with 10% MeCN/0.05% TFA, and elution of the retained material was
carried out with 80% MeCN/0.05% TFA. The eluate was lyophilized and kept frozen at −20 ◦C until
further analysis.
5.2. High Performance Liquid Chromatography (HPLC) and Mass Spectrometry
The SPE eluate was subjected to reversed phase high performance liquid chromatography
(RP-HPLC) using a SunFire Prep C18 (90 Å; 5 µm; 250 × 10 mm, Waters, Milford, MA, USA) or
a reverse-phase column Jupiter C5 (300 Å, 10 µm, 250 ×10 mm, Phenomenex, Torrance, CA, USA)
columns The eluate was separated using a linear gradient of 0–60% MeCN/0.05% TFA over 60 min,
and a flow rate of 5 mL/min. Fractions were dried under vacuum and reconstituted in MQ–H2O
before bioactivity testing. Active fractions were submitted for purity and mass measurements by mass
spectrometry (MS).
Peptide purity and mass measurements were conducted using HPLC hyphenated with
photodiode-array detection and electrospray ionization mass spectrometry (LC-PDA-ESI-MS).
The system (Waters) consisted of an Alliance 2690 separation module connected to a 2998 photodiode
array detector reading from 190 to 500 nm in 1.2 nm increments and a ZQ single quadrupole instrument,
equipped with an electrospray LC interface. Samples were dissolved in water. The samples were
separated using a Waters Sunfire C18 (5 µm, 2.1 × 100 mm) column. Linear gradients ran from 5 to
50% MeCN/0.05% TFA and a flow rate of 0.2 mL/min. MS analyses were performed in the positive
ion mode with a cone voltage of 30 V. N2 was used as desolvation gas (flow of 1000 L/h) and cone gas
(flow of 50 L/h). The data was recorded in the continuum mode of acquisition and the quadrupole
scanned from m/z 100 to 2000. Ion signals were recorded using the MassLynx v4.1 (Micromass) software
(Waters, Milford, MA, USA). The series of multiply charged protonated molecular ions acquired from
the scan were used to calculate non-protonated average molecular masses.
High resolution mass spectrometry (HR-MS) was conducted using a 1290 Infinity UHPLC
system hyphenated with a 6540 Q-TOF mass spectrometer with an ESI ion source, controlled by
the MassHunter software (all Agilent, Santa Clara, CA, USA). Linear gradients went typically from
5 to 60% MeCN/0.1% Formic Acid (FA) with a flow-rate of 0.4 mL/min and column heated to 40 ◦C.
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Acquisition was in the positive ion mode at 2 GHz, drying gas eight L/min, Nebulizer gas 35 Psig,
capillary voltage 3.5 kV, fragmentor 175 V, skimmer 65 V, m/z range varied with a maximum of 50–3200.
Drying and nebulizer gas was N2 and the reference masses were 121.050873 and 922.009798 Da.
Molecular weight measurement was also carried out by matrix-assisted laser desorption ionization
(MALDI), on an Ultraflex TOF-TOF (Bruker Daltonik, Bremen, Germany) instrument. The molecular
mass was determined in linear positive ion mode, using samples prepared by the dried droplet method
using as a matrix 2.5-dihydroxybenzoic acid (10 mg/mL in 70% acetonitrile with 0.1% TFA).
5.3. Sequencing and Structure Elucidation
Reduction was performed by dissolving ~20 nmol peptide in 100 µL 0.5 M Tris HCl/1 mM
EDTA/6 M guanidine HCl and adding 5 µL 2.2 M dithiotreitol (DTT; Sigma-Aldrich, St. Louis,
MO USA). The mixture was flushed with N2 to prevent oxidation and incubated for 16 h at 37 ◦C.
The following alkylation was achieved by adding 5 µL 4-vinylpyridine (Sigma-Aldrich, St. Louis, MO
USA) and incubating for 20 min at 37 ◦C. The reaction was stopped by RP-SPE, as previously described,
eluting with 80% MeCN/0.05% TFA. Reduction and alkylation of Ueq 12-1 followed by Edman
degradation sequencing were performed at Eurosequence (Groningen, The Netherlands). Protein
sequence data are available in the UniProt Protein Database under the accession number C0HK26.
5.4. Precursor Determination and Gene Synthesis
Total RNA of U. eques was purified from the tentacles using the Trisol® Reagent
(Ambion, Burlington, ON, Canada) as described in the manufacturer’s protocols. RNA reverse
transcription into cDNA was performed using the MINT kit (Evrogen, Moscow, Russia) according
to the manufacturer’s recommendations. Rapid amplification of cDNA ends (3′-RACE) with the
universal primer T7cap (GTA ATA CGA CTC ACT ATA GGG CAA GCA GTG GTA ACA ACG
CAG AGT), and degenerated primers UE-d1 (TGC TAC CCA GGA CAR CCN GGN TG) and UE-d2
(GTC CGA AYT AYT GYG ARG GNG C) was carried out for 3′-terminus determination. 5′-terminus
determination was performed by 5′-RACE using the universal primer T7cap, and the reverse primers
UE-r1 (CAA GCA CAG CAG CAT CTA TCT) and UE-r2 (AGC TAA AGT GCA CTA GCC GCA).
DNA sequencing was carried out using an ABI 3730 DNA Analyzer (Applied Biosystems, Carlsbad,
CA, USA). The cDNA sequence of Ueq 12-1 was submitted to EMBL Nucleotide Sequence Database
with submission number LT600337.
The DNA sequence encoding the peptide Ueq 12-1 was constructed from four synthetic
oligonucleotides using the PCR technique. The primers UE-dir1 (GAA GAT CTA TGT GCT ATC
CGG GCC AGC CGG GCT GCG GCC ATT GCT CCC GT) containing Met-codon for BrCN cleavage,
UE-dir2 (GCC ATT GCT CCC GTC CGA ATT ATT GCG AAG GCG CGC GTT GCG AAT CCG GC),
UE-rev1 (GAC TCG AGC TAC GCG CAG CAG CAA CGA TCG CCG GAC GCA TCG CAC CAA
TG), and UE-rev2 (CGC ATC GCA CCA ATG ATC GGA GCC GCA ATC ATG AAA GCC GGA TTC
GCA AC) were used for PCR fragment amplification. The target PCR fragment was gel-purified and
cloned into the expression vector pET32b+ (Novagen, Madison, WI, U.S.A). The resulting construct
was verified by sequencing using the ABI 3730 DNA analyzer. Nucleotide sequence data are available
in the European Nucleotide Archive under the accession number LT600337.
5.5. Bioinformatics
The BLAST search engine [55], the Antimicrobial Peptide Database [56], the InterProScan tool [57]
and StellaBase [58] was used to search for homologues sequences. The SignalP4.1 server [59] was
used to predict the potential cleavage site of the signal peptide with the default setting for D-cutoff
values and no TM regions selected. The theoretical molecular weight and the pI value of Ueq 12-1
were calculated using the Expasy program [60], while ChemCalc [61] was employed for theoretical
monoisotopic mass elucidation.
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5.6. Recombinant Peptide Production
The recombinant Ueq 12-1 was produced as a fusion protein with a thioredoxin domain using an
Escherichia coli SHuffle® T7 Express strain (New England Biolabs, Ipswich, MA, USA). The expression
vector was transformed into competent cells, which were then cultivated at 37 ◦C in LB medium
containing ampicillin at a concentration of 100 µg/mL. Expression was induced at a culture density
of ~0.6–0.8 (OD600) by adding isopropyl-1-thio-β-D-galactopyranoside up to 0.2 mM. The cells were
then cultivated for 18 h at 25 ◦C. After cultivation, the cells were harvested by centrifuging for 5 min at
6000× g, re-suspended in buffer for metal affinity chromatography (400 mM NaCl, 20 mM Tris-HCl,
pH 7.5), ultrasonicated, and centrifuged for 15 min at 9000× g to remove all insoluble particles. The
fusion protein was purified using the TALON Superflow metal affinity resin (Clontech, Mountain
View, CA, USA) according to the manufacturer’s protocol. The fusion protein was diluted to 1 mg/mL
and cleaved overnight with CNBr in the dark at room temperature, as previously described [62]. HCl
was added to a final concentration of 0.2 M, and the CNBr molar ratio to peptide was adjusted to
600:1. In order to isolate the properly folded recombinant peptide, the reaction mixture was subjected
to two separation steps: (1) RP-HPLC using a Jupiter C5 (250 × 10 mm, Phenomenex, Torrance,
CA, USA) column and a linear gradient from 0% to 60% MeCN over 60 min (flow of 10 mL/min);
and (2) RP-HPLC using a Vydac C18 (250 × 4.6 mm, Grace, Williamsburg, MI, USA) column and a
linear gradient from 0% to 40% MeCN over 40 min (flow of 1 mL/min). The purity of the peptide was
confirmed by MALDI-TOF MS and N-terminal sequencing.
5.7. NMR Spectroscopy and Calculation of Spatial Structure
The NMR sample was prepared by dissolving 0.8 mg of recombinant Ueq 12-1 in 350 µL buffer
containing 5% D2O, 1 mM sodium azide, pH 3.2. All spectra were recorded at 303 K using a
Bruker Avance III 600 MHz spectrometer (Bruker BioSpin, Billerica, MA, USA), equipped with triple
resonance cryogenic probe. Proton, 15N and 13C resonance assignment was obtained via the standard
procedure [63], based on the MLEV-TOCSY (80 ms mixing time), NOESY (40 and 80 ms mixing times),
1H, 13C-HSQC, 1H, 15N-HSQC and DQF-COSY spectra. After the set of NMR spectra was recorded,
the sample was lyophilized and dissolved in pure D2O buffer as described above with the same
contents to measure the rate of proton-deuterium exchange of amide groups, and additional NOESY
(80 ms mixing time) and DQF-COSY were recorded.
Spatial structure calculation was performed using the simulated annealing/molecular dynamics
protocol as implemented in the CYANA software package version 3.0 (L.A.Systems, Inc., Taito Tokyo,
Japan) [29]. Upper interproton distance constraints were derived from the NOESY (τm = 80 ms)
cross-peaks via a 1/r6 calibration. Torsion angle restraints and stereospecific assignments were
obtained from J couplings and NOE intensities. 3JHNHα couplings were measured by the lineshape
analysis of the cross-peaks in NOESY spectra and 3JHαHβ coupling constants were obtained using the
ACME software [64] in the DQF-COSY spectrum of Ueq 12-1 in D2O solution (relaxation delay 3 s).
Hydrogen bonds were introduced based on the deuterium exchange rates of amide protons. Disulfide
connections were determined in the course of the structure calculation.
Visual analysis of the calculated structures and figure drawings were made using the MOLMOL
software (version number 2k2) [65]. The obtained spatial structure was validated and analyzed using
the PDB-sum server [66]. Analysis of the 3D structure homology was performed by the PDBeFold
analysis tool [37]. Potential grid was calculated using APDS software [67]. Chemical shifts, NMR
constraints and derived atomic coordinates (10 models) of Ueq 12-1 were deposited into the Protein
Data Bank [68], accession code 5LAH.
5.8. Antibacterial Activity Assay
Antibacterial activities were tested against a selection of Gram-positive and Gram-negative
bacteria: Corynebacterium glutamicum (ATCC 13032), Staphylococcus aureus (ATCC 9144), Pseudomonas
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aeruginosa (ATCC 27853), and Escherichia coli (ATCC 2592). All isolates were grown at room temperature
in Mueller Hinton Broth (MHB; Difco Laboratories, Detroit, MI, USA). Peptide concentration
was determined by weighing and was diluted in water to a concentration of 200 µM and serial
twofold dilutions were made before antibacterial activity testing. Antibacterial screening and
minimal inhibitory concentration (MIC) determination were performed in 96-well microtitre plates, as
previously described [69]. Briefly, 50 µL of test fractions were incubated with 50 µL of a suspension of
an actively growing culture of bacteria diluted to a final concentration 1.3 − 1.5 × 104 bacteria/mL.
Bacterial growth was assayed every hour by measurement of the optical density (OD595) using Envision
2103 multilabel reader, controlled by the Wallac Envision manager (PerkinElmer, Waltham, MA, USA).
The MIC value was defined as the lowest concentration of peptide resulting in no bacterial growth as
determined by OD595 measurements. The purified peptide was tested in two parallels.
5.9. TRPA1 Activity Assays
The TRPA1 gene (AY496961.1) was amplified from rat brain, cloned into a pcDNA4TO vector
and sequenced.
5.9.1. Fluorescent Assay of Calcium Influx
The cell line CHO (Chinese Hamster Ovary), stably expressing rat TRPA1, was produced using
the T-Rex System (Thermo Fisher Scientific Inc., Waltham, MA, USA) according to the manufacturers’
protocol. Shortly, a vector pcDNA4/TO with cDNA encoding rat TRPA1 was made, and transfected
into CHO cells carrying the regulatory vector pcDNA6/TR (encoding the tetracycline repressor).
The CHO cells were grown at 37 ◦C and 5% CO2 in DMEM/F12 (1:1) medium containing 10% fetal calf
serum, After 2 weeks of selection by blasticidin (5 µg/mL) and zeocin (250 µg/mL), single colonies were
screened using the agonist-induced [Ca2+] uptake assay. TRPA1 expression was induced by adding up
to 1 µg/mL tetracycline 24 h before testing. Positive clones were used for experimentations. Fluorescent
assays were performed using a tablet spectrophotometer with integrated automatic liquid dosing
system NOVOstar (BMG LABTECH, Ortenberg, Germany). rTRPA1-CHO cells were seeded into
black-walled clear-bottomed 96-well plates at a density of 75,000 cells per well and cultured overnight
at 37 ◦C (complete media containing 1 µg/mL of tetracycline). TRPA1-expressing cells were stained
with the calcium indicator Fluo-4AM using the Fluo-4 Direct™ Calcium Assay Kit (Thermo Fisher
Scientific Inc., Waltham, MA, USA), and incubated in the dark successively at 37 ◦C and 25 ◦C for 60 min
each time. The control (buffer alone) and serial dilutions of Ueq 12-1 (concentrations ranging from
0.3 to 750 µM) were added to the cells and measurements were immediately carried out. Fluorescent
signals were monitored before and after the addition of the TRPA1 agonist. The measurements were
performed at room temperature and pH 7.4.
5.9.2. Electrophysiology
cRNA of TRPA1 (AY496961.1) was synthesized from a NarI-linearized pVAX1/TRPA1 plasmid
using a HiScribe™ T7 High Yield RNA Synthesis Kit (New England Biolabs, Ipswich, MA, USA)
according to the manufacturers’ protocol for capped transcripts. The cRNA transcripts (2–5 ng) were
injected in Xenopus laevis oocytes. The injected oocytes were incubated for 2–7 days at 15–19 ◦C
in sterile ND-96 medium containing 100 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2,
5 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid HEPES, pH 7.4, supplemented with
50 µg/mL gentamycin.
Electrophysiological measurements were carried out in a bath perfused with Ca2+-free solution
that contained 100 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 5 mM HEPES, pH 7.4. Oocytes were
impaled with two glass microelectrodes filled with 3 M KCl and connected to a GeneClamp 500
amplifier (Axon Instruments, Union City, CA, USA). Oocytes were clamped at −20 mV, recording
of inward/outward currents made at repeated step to −100 mV for 80 ms following voltage ramp
from −100 mV to +100 mV for 200 ms every 4 s. Diclofenac (300 µM in Ca2+-free solution) [70] or
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Allyl isothiocyanate (AITC, 100 µM in Ca2+-free solution) [71] were used to activate the channel.
Experiments were performed at room temperature (22–24 ◦C). The data were filtered at 20 Hz and
digitized at 100 Hz by an AD converter L780 (LCard, Moscow, Russia) using in-house software.
5.10. In Vivo Experiments
5.10.1. Animal Models
All experiments were approved by the Animal Care and Use Committee of the Branch of the
IBCh RAS (Pushchino, Russia) protocol number No. 492/16. Adult male CD-1 mice (weight 20–30 g;
obtained from the Animal Breeding Facility Branch of Shemyakin-Ovchinnikov Institute of Bioorganic
Chemistry, Russian Academy of Sciences, Pushchino, Russia Federation) were housed at room
temperature (23 ± 2 ◦C) and subjected to a 12 h light–dark cycle with food and water available
ad libitum. Ueq 12-1 was dissolved in saline. The significance of the data was determined by Analysis of
variance (ANOVA) followed by Turkey’s post-hoc test. Data are presented as mean ± SEM. No explicit
power analysis was performed prior to the experiments to determine sample size, since we had no
means to reliably estimate the size and variability of the effects of the peptide on mice. Since highly
significant results were obtained from this set of experiments, no further animals were sacrificed.
5.10.2. Test on Pain/Thermal Hyperalgesia-Evoking Activity
Ueq 12-1 (2.5 µg/10 µL) or saline (10 µL) were injected into the left hind-paw. Licking and
guarding behavior was monitored for 15 min after injection. Withdrawal latency of injected hind-paw
from a hot plate (53 ◦C) was observed 2 h after injection.
5.10.3. “Open Field” Test on Locomotor Activity
The effects of Ueq 12-1 on spontaneous locomotor activity of mice were assessed using TSE
Multi Conditioning System Extended Advanced with TSE ActiMot (Activity & Hole Board Measuring
System) module and test arena “Open field” (TSE Systems, Inc. Chesterfield, MO, USA). Locomotor
activity was recorded for 15 min. Peptide (0.2 mg/kg) and saline were administered intravenously
(i.v.) 30 min before testing.
5.10.4. Allyl Isothiocyanate (AITC)-Induced Nocifensive Beaviour
The TRPA1 agonist AITC was used to activate peripheral TRPA1 receptors and induce nocifensive
behaviors in mice [72]. To produce nocifensive behavioral response AITC (20 µL, 0.5% in saline) was
injected into the plantar surface of the hind-paw. Ueq 12-1 (0.2 mg/kg) or saline were administrated i.v.
30 min before AITC administration. The duration of paw guarding and number of licks were recorded
for 5 min after injection of AITC. The diameter of the paw was evaluated before the test and 2, 4 and
24 h after injection using an electronic digital caliper.
5.10.5. Complete Freund’s Adjuvant (CFA)-Induced Inflammation and Thermal Hyperalgesia
Paw inflammation and thermal hyperalgesia was induced using Complete Freund’s Adjuvant
(CFA) suspended in an oil/saline (1:1) emulsion. The mice were injected with 20 µL of CFA emulsion
into the plantar surface of the left hind-paw. The control mice were injected with 20 µL of saline. After
24 h, Ueq 12-1 (0.2 mg/kg and 1 mg/kg) or saline were i.v. administrated. Paw withdrawal latency
was recorded using a hot plate (53 ◦C) 30 min after peptide or saline administration. The diameter
of the paw was evaluated before CFA injection, before Ueq 12-1 or saline administration and 2, 4,
24 h after Ueq 12-1 or saline administration using electronic digital caliper. Percent inflammation was
calculated according to the formula ((Postdose paw diameter − Naive paw diameter)/(Predose paw
diameter − Naive paw diameter)) × 100.
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